Without social change or new therapies, alcohol-associated liver disease (ALD) and metabolic dysfunction–associated steatotic liver disease (MASLD; formerly called nonalcohol-related fatty liver disease) will likely
In patients with the rare, chronic cholestatic liver disease of primary biliary cholangitis, elafibranor significantly improved relevant biochemical indicators, researchers report. “The majority of patients
For treating recurrent bleeding caused by small-intestinal angiodysplasia (SIA), thalidomide significantly reduced bleeding compared with placebo, a Chinese study shows. “The results of the current trial
The long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue pegozafermin improved fibrosis in a phase 2b trial of patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH). “These
Based on a review of available clinical literature on the management of Wilson’s disease, the authors describe the current advances in the diagnosis, treatment, and
Proton pump inhibitor (PPI) use may be an important and preventable source of fatigue and reduced health-related quality of life (HRQoL) in people who received
Compared with 3 or fewer servings of sugar-sweetened soft drinks or fruit drinks per month, 1 or more servings of these sugar-sweetened beverages per day
Mirikizumab, a p19-directed antibody against interleukin-23, was “more effective than placebo in inducing and maintaining clinical remission in patients with moderately to severely active ulcerative
Among 352 women in early pregnancy with moderate-to-severe nausea and vomiting, acupuncture and doxylamine–pyridoxine individually were efficacious but with modest effects of uncertain clinical importance.
In patients with moderate-to-severe Crohn’s disease, the oral selective Janus kinase (JAK) inhibitor upadacitinib was superior to placebo when used for induction and maintenance treatment,